PAPPA and preeclampsia: In 2023, the FDA approved the use of PlGF, PAPP‐A, maternal factors, uterine artery pulsatility index (UtA‐PI), and mean arterial pressure, all in combination, to predict preeclampsia following a study by the Fetal Medicine Foundation (FMF) [46].